Pharmacokinetics of Octreotide in Patients With Cirrhosis and Portal Hypertension; Relationship Between the Plasma Levels of the Analogue and the Magnitude and Duration of the Reduction in Corrected Wedged Hepatic Venous Pressure release_w3uqnv6sf5ajno3yqufpcma5uu

by S. A. Jenkins, D. M. Nott, J. N. Baxter

Published in HPB Surgery by Hindawi Limited.

1998   Volume 11, p13-21

Abstract

In healthy subjects octreotide is largely metabolised by the liver suggesting that the plasma half-life of the somatostatin analogue may be prolonged in patients with hepatic dysfunction. The aim of this study was therefore (a) to determine the pharmacokinetics of octreotide following its subcutaneous injection in 6 patients with cirrhosis and portal hypertension and (b) compare the magnitude and duration of the effects of intravenous administration of 250 μg somatostatin and 50 μg octreotide on corrected wedged hepatic venous pressure (WHVP) and to relate the findings to the plasma levels of the analogue 1h after administration in 13 patients with cirrhosis and portal hypertension. Following subcutaneous administration of 50 μg octreotide the circulating half life (range 2.4 to 4.79 h) was prolonged whereas the clearance (range 2.101 to 4.775 L/h) was decreased compared to healthy controls. Intravenous bolus administration of 25 μg somatostatin or 50 μg octreotide resulted in a reduction in WHVP of approximately the same magnitude and duration despite appreciable quantities of the analogue in the blood lh after administration (1944 ± 226 pg/ml). These results indicate that the circulating half-life of octreotide is prolonged in cirrhotics suggesting that the dosage regimens should be modified in such patients to avoid accumulation of the analogue in the blood which may result in undesirable side-effects or toxicity. Furthermore, since the magnitude and duration of the reduction in WHVP elicited by IV octreotide is similar to that obseved with somatostatin, the analogue, like the native hormone, must be administered by continuous IV infusion to produce a sustained response and hence a therapeutic effect in the management of acute variceal bleeding.
In application/xml+jats format

Archived Files and Locations

application/pdf  709.1 kB
file_f2ftydbdoje57hkc6kzj7loqja
europepmc.org (repository)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Year   1998
Language   en ?
DOI  10.1155/1998/17436
PubMed  9830576
PMC  PMC2423925
Wikidata  Q36712916
Container Metadata
Open Access Publication
Not in DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  0894-8569
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: c3308bf8-8ebe-43d6-93ba-91ba929e8c34
API URL: JSON